Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05439226
Other study ID # Version 2.0
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 5, 2022
Est. completion date May 5, 2024

Study information

Verified date October 2023
Source State Key Laboratory of Subhealth Intervention Technology
Contact Luo wu
Phone 13687333270
Email luowubio@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Type 2 diabetes (T2D) represents a serious public health problem. Patients with T2D and non-alcoholic fatty liver disease(NAFLD) demonstrate a poor metabolic profile and increase mortality compared with patients with only NAFLD or T2D. Nutritional intervention is the most basic treatment for T2D. Previous study showed that a Chinese medical nutrition therapy (CMNT) diet, which intermittent use of low-calorie medicinal food, has a glucose-lowering effect in T2D. This study aims to investigate the effect of a Chinese medical nutrition therapy (CMNT) diet accompanied by intermittent energy restriction on reducing liver fat and glycated hemoglobin (HbA1c) in patients with T2D and NAFLD.


Description:

Diet composition of CMNT is a multicomponent Chinese medicinal food, which mainly enriched with whole grains and edible medicine and food homologous (MFH) plants such as Rhizoma Dioscoreae, Momordica Grosvenori, Folium Mori, Radix Puerariae, Fructus lycii, Poria cocos that meets the requirements of a food for special medical purpose. The CMNT group was instructed to consumed the provided CMNT diet consisting of 6 cycles of 5 consecutive days followed by 10 days of ad libitum food consumption. Participants received a 917 kcal/day preprepared human CMNT diet (44.75% carbohydrate, 9.1% protein and 46.15% fat) for 5 consecutive days per cycle. CMNT diet is composed of four ready-to-consume prepared foods including composite nutritional rice, solids beverages, meal replacement biscuit and fruit and vegetable gruel mainly from wholegrains and traditional Chinese medicinal food plants. The intervention lasted for 3 months (6 cycles) and follow-up measurements will be performed in all subjects after 3-months from end of the intervention. The glucose-lowering medication use of participants strictly implemented by their physician according to the diabetes medications management protocol. Treatment-as-usual control group continued to be given standard medication and dietary advice by their physician followed guidelines for the prevention and control of T2D in China.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date May 5, 2024
Est. primary completion date June 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients diagnosed with type 2 diabetes and NAFLD - Age between 18 and 75 years - BMI between 18.0 and 35.0 kg/m2 - Weight stable for at least 3 months prior to the study (gain or loss < 4 kg) - Stable treatment for at least 3 months with 1-3 oral antidiabetic medications (with or without insulin therapy), or not yet received antidiabetic medication prior to the beginning of the study - Able to give written informed consent Exclusion Criteria: - Self-reported a food allergy - Alcohol abuse in the last 3 months (alcohol intake greater than 20 g per day for women; Alcohol intake for men greater than 40 g per day) - Other liver diseases such as chronic hepatitis B and C, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, nodular regenerative hyperplasia and focal nodular hyperplasia - Scheduled to be hospitalized for any surgical treatment during screening - Pregnant or planning of pregnancy during the study - Inability, physically or mentally, to adhere the procedures required by the study protocol - Level 3 hypoglycemic events (at least 3 times) occurring within the 90 days prior to screening - Hospitalization or emergency department visit for hyperglycemia, diabetic ketoacidosis, lactic acidosis, hyperosmolar nonketotic coma, or diabetes - History of cancer within the past 5 years - Acute coronary or cerebrovascular event in the past 90 days, or heart failure - Hemorrhagic or ischemic stroke within the last 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
CMNT diet
Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet

Locations

Country Name City State
China Hunan Shanshui physical examination center Changsha Hunan
China Jinheyuan Outpatient Department, National Sub-health Intervention Technology Achievement Application Center Changsha Hunan
China Physical Examination Center of Gezhouba central hospital of Sinopharm Yichang Hubei

Sponsors (1)

Lead Sponsor Collaborator
State Key Laboratory of Subhealth Intervention Technology

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Controlled attenuation parameter (CAP) value by transient elastography The CAP score, which be measured by FibroScan, will be used to quantify and detect liver fat. CAP < 238 dB/m indicated no hepatic steatosis, 238 = CAP = 259 dB/m denoted mild steatosis, 260 = CAP =291 dB/m indicated moderate steatosis, and CAP > 291 dB/m denoted severe steatosis. 3, 6, 12, 24 months
Primary HbA1C Blood test to measure glucose control 3, 6, 12, 24 months
Secondary Fatty liver index (FLI) FLI will also be applied to quantify the degree of steatosis of patients with type 2 diabetes and NAFLD. FLI values < 30 rule out liver steatosis, whereas FLI = 60 confirmed NAFLD with a specificity of 61%. 3, 6, 12, 24 months
Secondary Hepatic steatosis index (HSI) HSI will also be applied to quantify the degree of steatosis of patients with type 2 diabetes and NAFLD. HSI values < 30 excludes NAFLD with a sensitivity of 93.1%, while values > 36 detected NAFLD with a specificity of 92.4%. 3, 6, 12, 24 months
Secondary Liver stiffness measurement (LSM) value by transient elastography Liver fibrosis will be assessed by using a non-invasive vibration-controlled transient elastography to estimate LSM. A median LSM = 8.2 kPa was considered indicative of significant fibrosis (= F2), whereas LSM = 9.7 kPa was considered indicative of advanced (= F3) fibrosis, whereas LSM = 13.6 kPa was considered indicative of cirrhosis (F4). 3, 6, 12, 24 months
Secondary Fibrosis-4 index (FIB-4) The FIB-4 index, a non-invasive measurement, will be used to evaluate the degree of liver fibrosis. The FIB-4 index <1.45 had a negative predictive value of 94.7% to exclude progressive fibrosis, whereas FIB-4 index >3.25 was considered advanced fibrosis or cirrhosis. 3, 6, 12, 24 months
Secondary NAFLD fibrosis score (NFS) Degree of liver fibrosis will also be assessed by NFS.The probability of advanced liver fibrosis was classified into three groups: high NFS (NFS > 0.676), intermediate NFS (NFS: -1.455 to 0.676, or 0.120 to 0.676 if age > 65), or low NFS (NFS < -1.455, or < 0.120 if age > 65) . 3, 6, 12, 24 months
Secondary Liver function test ?-glutamyl transferase (?-GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and ect will be assessed. 3, 6, 12, 24 months
Secondary Blood glucose Fasting plasma glucose (FPG) and postprandial 2-hour plasma glucose (2 h-PG) 3, 6, 12, 24 months
Secondary Blood lipid triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) 3, 6, 12, 24 months
Secondary Insulin Glucose homeostasis 3, 6, 12, 24 months
Secondary HOMA-IR Fasting glucose times fasting insulin divided by 22.5 3, 6, 12, 24 months
Secondary IGF-1 Glucose homeostasis 3, 6, 12, 24 months
Secondary Body mass index Body mass in kilograms divided by height in meters squared. 3, 6, 12, 24 months
Secondary waist-to-hip ratio Waist circumference in centimeter divided by height in centimeter. 3, 6, 12, 24 months
Secondary Blood pressure Systolic blood pressure and diastolic blood pressure. 3, 6, 12, 24 months
Secondary Energy intake 3-day diet record and Food Frequency Questionnaire 3, 6, 12, 24 months
Secondary Macronutrient intake 3-day diet record and Food Frequency Questionnaire 3, 6, 12, 24 months
Secondary Sleep quality Pittsburgh Sleep Quality Index Questionnaire 3, 6, 12, 24 months
Secondary Physical activity International Physical Activity Questionnaire 3, 6, 12, 24 months
Secondary Self-reported depressive symptoms Patient Health Questionnaire 9 3, 6, 12, 24 months
Secondary Anxiety symptoms Generalized Anxiety Disorder scale 3, 6, 12, 24 months
Secondary Social support Social Support Rate Scale 3, 6, 12, 24 months
Secondary Reduction in glucose-lowering medication Reduction in total dose of glucose-lowering medications 3, 6, 12, 24 months
Secondary Fecal microbiota profile Fecal samples will be collected and will be sequenced. 3, 6, 12, 24 months
Secondary Metabolomics Blood, fecal and urine samples will be collected and metabolites will be analyzed through a metabolomics approach. 3, 6, 12, 24 months
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A